Thromboprophylaxis after discharge

One figure that shifts the perspective

Discussion of thromboprophylaxis centres on the inpatient stay. The data cited by the S3 guideline on VTE prophylaxis in chapter 10 suggest a different centre of gravity.

A retrospective analysis of 529,492 hospitalised patients with six-month follow-up found 77.6 per cent of VTE events after discharge. The average length of stay in German surgical and internal medicine departments in 2023 was five days.

A meta-analysis of 22 studies with 1,864,875 patients and 24,927 VTE events shows how postoperative symptomatic events are distributed over time:

The distribution is largely consistent across the surgical populations studied. Taken together, most of the risk window lies outside the hospital — in the rehabilitation clinic, the care facility, at home.

What the guideline derives from this

Three passages are relevant.

Duration follows the risk, not the discharge date

Recommendation 10.3, grade A: the duration of pharmacological VTE prophylaxis shall be guided by the persistence of relevant risk factors. The guideline adds that it is sensible to carry out a renewed risk assessment at the end of inpatient treatment for the post-acute phase — explicitly naming the rehabilitation facility or outpatient care — and to adjust measures accordingly.

Handover is part of prophylaxis

Recommendation 10.4: where continuation is planned and responsibility changes, handover to those continuing treatment shall be ensured and the patient encouraged to present there, so that VTE prophylaxis remains uninterrupted.

Chapter 19.1: after discharge, the indication and duration of continuation shall be reviewed against the individual risk situation. On transfer to outpatient care, written documentation shall be provided stating indication, type and dosage and, where applicable, the most recent laboratory values.

For stroke the guideline is more specific

Recommendation 19.3 (new in 2025, grade 0): after acute stroke, with persisting restricted mobility or further risk factors, pharmacological prophylaxis may be continued for four to five weeks after discharge.

Where it becomes practical

These recommendations mostly concern pharmacological prophylaxis. For device-supported prophylaxis the guideline states plainly elsewhere that continuation of IPC in rehabilitation facilities cannot always be ensured and that IPC application may interfere with rehabilitation measures.

That is not an efficacy problem but a delivery problem — and it names precisely the gap at issue here. Two things can be set against it, both documented:

• Application window. Efficacy of IPC in stroke is documented from an application time of at least 18 hours per day (RR 0.50; meta-analysis of 7 RCTs with 3,551 patients). That covers rest, night and recumbent phases and leaves therapy blocks free. Conflict with rehabilitation arises mainly where device and therapy schedule are not coordinated.
• Availability. “Cannot always be ensured” describes an organisational reality, not a medical necessity. Whether an indicated measure can be continued depends on device availability, trained staff and predictable resupply of cuffs.

Worth noting alongside: the guideline reports adverse events including disturbed sleep patterns, skin injuries and an increased risk of falls, with an incidence of 2.89 per cent versus 1.29 per cent in the control group. Application technique, cuff selection and wear time are therefore part of the measure.

What this means for the receiving facility

• Renewed risk assessment on admission rather than carrying the discharge letter forward. The guideline requires it explicitly for the post-acute phase.
• Reliable handover. What was started in hospital has to arrive documented — indication, type, dosage, duration.
• Availability of the indicated measure. Where pharmacological prophylaxis is contraindicated, physical measures shall be applied, preferably intermittent pneumatic compression — recommendation 7.3, grade A. That holds regardless of which facility the patient is in.

Where the guideline is silent

For care facilities the S3 guideline contains no dedicated chapter. Anyone looking for a specific recommendation there will not find one; the reasoning runs through the general recommendations on risk and immobility and through 7.2, 7.3 and 7.4. Nor is there a German nursing expert standard on thromboprophylaxis — see Is there an expert standard on thromboprophylaxis?.

Unchanged: physical measures shall not replace an indicated pharmacological prophylaxis (recommendation 7.2). The specific indication is always determined by the treating professionals. This article addresses medical professionals.